52-Week Highs and Lows, Monday May 4, 2026

10 new highs. 2 new lows.

Highs

CASY .. $857.86 .. Casey's General Stores. Eight day winning streak into a fresh ATH. KeyCorp lifted target to $860 Overweight, Zacks went Strong Buy, S&P 500 Equal Weighted inclusion adds passive demand. Premium grinder, P/E now ~47.

JAZZ .. $208.53 .. Jazz Pharmaceuticals. FDA priority review accepted for Ziihera (zanidatamab) in 1L HER2+ gastroesophageal cancer, PDUFA August 25. Q1 prints Tuesday after close. Large cap pharma running into the catalyst.

ETON .. $31.12 .. Eton Pharmaceuticals. Hemangeol relaunched May 1 via Anovo Specialty Pharmacy with $0 co-pay program. ET-700 Wilson disease pilot dosed first patient April 27, topline 2H 2026. Q1 May 14. Multi-product rare disease engine quietly compounding.

AURA .. $8.49 .. Aura Biosciences. Priced $260M offering at $6.00 and still ripped +19% on the day. Massive demand. Funds bel-sar Phase 3 CoMpass and a buyback from Matrix Capital. New CEO Natalie Holles starts April 30. Going concern flag is now off the table.

DRTS .. $9.07 .. Alpha Tau Medical. Hit fresh ATH intraday then reversed hard, closed $7.53, down 11.8% on the session. Shelf overhang and ATM via HC Wainwright still pressuring. Profit taking after DDW pancreatic data run. Watch the next leg carefully.

ASTH .. $35.85 .. Astrana Health. Value based care compounder. Q1 prints Thursday May 7 after close. Baird raised target to $40 Outperform. Prospect Health adds $1.2B revenue and $81M EBITDA on a full year basis.

ABSI .. $5.67 .. Absci. AI drug discovery, up ~14% on the day. ABS-201 anti-PRLR for androgenetic alopecia headed into Phase 1/2a, endometriosis advisory board added. Needham at $7 Buy. Q1 May 19. Miami Tier 2 name.

CABA .. $4.05 .. Cabaletta Bio. $150M raise with Lilly announced same day, +30% pop. Autoimmune CAR-T. Fits the calibration fix for autoimmune CAR-T heat where big pharma is actively writing checks.

LION .. $12.84 .. Lionsgate Studios. Pure play content, active M&A setup with Netflix chatter. Morgan Stanley Overweight $14, Benchmark Buy raised $12 to $15. "Michael" opened to $217M record box office. M&A Watch.

CARE .. $26.27 .. Carter Bankshares. Virginia and North Carolina regional bank, $573M cap. Q1 net income $85.8M including $98M gain on the legacy nonperforming loan sale. Bearing Insurance sale adds $35.8M pre-tax gain in Q2. Hovde lifted target to $28, Raymond James reaffirmed Outperform $27. 1Y total return +68%. Local regional bank target thesis playing out.

Lows

PMI .. $0.35 .. Picard Medical. $5M offering pricing. Micro cap stuck below $1.

ABT .. $87.30 .. Abbott Laboratories. Mega cap dividend name down ~30% from highs. Yield play getting attention here.

Summary

Heavy session for biotech with five names tagging fresh highs across rare disease (ETON), oncology (JAZZ), AI discovery (ABSI), ocular (AURA) and autoimmune CAR-T (CABA). Two of those came on capital raises that were absorbed cleanly, AURA at +19% on a $260M deal and CABA at +30% on the Lilly partnership. That is the tape telling you where the demand is. DRTS the only red flag in the high list, ATH then a 12 point reversal on shelf overhang. Outside biotech, CASY keeps grinding, LION running on M&A buzz and box office, CARE proving the regional bank cleanup thesis. PMI and ABT the only two on the low list and they are at opposite ends of the cap spectrum.